Nanoparticle Strategies for Crossing the BBB in Alzheimer’s Disease

Abstract

Alzheimer Disease is the number-one source of cognitive deterioration across the globe and therapeutic advancements in
treating this disease are largely limited by both the defense and limitation protecting the brain by the Blood-Brain Barrier
(BBB). The fact that conventional drugs are not able to penetrate the BBB has led to the development of superior delivery
systems. Strategies involving nanoparticles have become a solution of prospect, as they offer better permeability, targeted
delivery and increased therapeutic efficacy. This research gives the systematic discussion of nanoparticle methods aimed at
conquering the BBB hurdle in the management of the disease of Alzheimer.
The review summarizes the recent progress in nanoparticle design, such as polymeric, lipid-based, metallic, and biomimetic
systems, focusing on how they carry their cargo such as receptor-mediated transcytosis, and adsorptive-mediated transportation.
Strategies involving functionalization of the conjugates are under discussion (ligand conjugation, PEGylation, and changes in
surface charges) and play a critical role in enhancing targeting specificity and systemic stability. Other delivery methods such
as intranasal delivery are also considered on account of their ability to circumvent the BBB limitations.
Recent research indicates that nanoparticle-mediated delivery systems can be used to increase the bioavailability of drugs, help
clear the amyloid-beta, regulate neuroinflammation, and deliver gene-based therapies. Moreover, theranostic nanoparticles
combining diagnostic imaging with therapeutic medicinal properties are also a major breakthrough in precision medicine.
Regardless of these encouraging progress, issues of toxicity, mass production, and regulatory acceptance still exist.
On balance, nanoparticle strategies can be discussed as a revolutionary way out of the BBB-related limitations, and the
opportunity to find new ways of effective treatment of Alzheimer disease. More innovation and research in nanoparticle
engineering and translational research should continue to close the gap between experimental achievement and clinical use.